NYR :Improved Drug Candidate Selected for WRAIR Studies

• New lead drug candidate NYR-BI01 advances to efficacy studies in collaboration with the Walter Reed Army Institute of Research (WRAIR)
• NYR-BI01 showed improved potency, along with excellent Pharmacokinetic (PK) properties and blood-brain barrier penetration
• Drug levels in the brain were significantly higher than those required to deliver a therapeutic effect and NYR-BI01 was well-tolerated throughout the 72-hour study
• WRAIR study to commence in H2 2021 with results expected in Q4 2021